FindTrial
Sign In

An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/r/ABT-267 Co-administered With Ribavirin for 12 or 16 Weeks in Treatment-Naive and Treatment-Experienced Japanese Adults With Genotype 2 Chronic HCV Infection With and Without Compensated Cirrhosis (GIFT-II)

An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/r/ABT-267 Co-administered With Ribavirin for 12 or 16 Weeks in Treatment-Naive and Treatment-Experienced Japanese Adults With Genotype 2 Chronic HCV Infection With and Without Compensated Cirrhosis (GIFT-II)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222382
Enrollment
Unknown
Registered
2014-01-31
Start date
2014-01-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C Virus

Interventions

investigational material(s) Generic name etc : ABT-450/r/ABT-267 INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational mat

Sponsors

AbbVie GK
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Chronic HCV-infection prior to study enrollment -Screening laboratory result indicating HCV genotype 2 infection -Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening -Voluntarily sign an informed consent

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026